Cabaletta Bio - AI Stock Analysis

Analysis generated January 25, 2026

Cabaletta Bio is a biotechnology company focused on discovering and developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases and other serious conditions. The company aims to harness the power of T cells in order to address diseases that current therapies have been unable to effectively treat.

Fundamental Analysis

When analyzing the fundamentals of Cabaletta Bio, it’s important to note the patterns in their financial performance:

• Revenue: The revenue for the last quarter was zero, matching the revenue of the previous quarter and the same quarter last year. This consistency indicates stability but also raises questions about the company's ability to generate revenue.
• Net Income: The net income for the last quarter stood at $45 million, representing a 0.58% increase from the previous quarter. However, when compared to the same quarter last year, there is a 46.48% decrease, which could be concerning for long-term investors.
• EBITDA: The EBITDA for the last quarter was $44 million, a 0.34% increase from the previous quarter, which is a positive sign of growth. Nonetheless, compared to the same quarter last year, there is a notable 45.46% decrease, indicating potential profitability issues.

Technical Analysis

Analyzing the stock price and technical indicators provides insight into the market's perception and the stock's performance:

• Stock Price: Today's stock price is $3.18. This represents a significant 45.21% increase compared to a month ago, indicating a strong positive short-term trend. Compared to a year ago, the stock price has increased by 27.20%, suggesting a positive long-term trend. The overall trend is bullish.
• SMA10: The current SMA10 is 2.58, higher than the previous SMA10 of 2.47, indicating a potential upward price movement.
• RSI: The RSI is 59.3, indicating a neutral condition, which suggests that the stock is neither overbought nor oversold at the moment.

Alternative Data Analysis

Alternative data provides additional insights into Cabaletta Bio's current state and potential for future growth:

• Job Postings and Employee Sentiment: Cabaletta Bio currently has 6 open positions, a 200% increase in the last couple of months, which signifies potential growth and expansion. Employee sentiment remains neutral, which does not provide a strong signal either way.
• Customer Acquisition: The estimated number of visitors to their webpage is 10,000, down by 50% in the last couple of months. This decline might indicate a potential loss in customer interest or engagement, which could be a red flag.
• Customer Engagement: The company has 540 followers on their Twitter page, which is up by 3% in the last couple of months. This points to a slight increase in interest and engagement with the company.
• AI Score: According to AltIndex's AI score, Cabaletta Bio has a score of 53, which signals a hold recommendation.

Conclusion

Based on the analysis, Cabaletta Bio presents a mixed picture. The fundamental data shows some concerning signs in terms of revenue and profitability trends, but stability in revenue. The technical indicators are largely positive, suggesting a bullish trend in the short and long term. The alternative data is somewhat mixed, with positive signals from job postings and social media engagement, but negative signals from web traffic.

Given this mixed data, a hold recommendation is the most prudent course of action. Investors should keep an eye on future earnings reports, customer engagement trends, and any further developments in the company's engineered T cell therapies, which could greatly impact the stock's future performance.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.